Category: Behind the Science
-
New frontiers in inflammasome therapeutics
Insights from Atuka’s recent visit to the 6th Annual Inflammasome Summit in Boston.
-
What the market overlooked in Seelos’s recent trehalose study
Atuka’s Jonathan Brotchie and Patrick Howson take a deeper look at the top-line results for IV trehalose, an ALS treatment, and see signs of potential for the compound that the market may have missed.
-
Tavapodon offers great promise as a new therapeutic for Parkinson’s disease
On the encouraging topline results from Cerevel Therapeutics’ Phase III TEMPO-3 trial for tavapadon, a D1/D5 dopamine receptor partial agonist.